Radioembolization With Intra-arterial Angiotensin II to Improve Tumor-absorbed Dose (RADIANT)

This clinical trial will test whether a short infusion of a drug called angiotensin II (AT-II) can make a liver cancer treatment work better. The drug is given directly into the artery that supplies blood to the liver, right before a treatment called yttrium-90 (90Y) radioembolization. The main questions it aims to answer are: * Does angiotensin II help more of the radioactive beads reach the tumor and less reach the healthy parts of the liver? * Is it safe to add angiotensin II to the standard radioembolization treatment? What will participants do? * First visit (work-up): Participants will

Trial Details

NCT ID

NCT07312292

Phase

PHASE2

Sponsor

Niek Wijnen

Status

RECRUITING

Cancer Type

Liver Cancer

Interventions

• Angiotensin II (Giapreza®)
• Yttrium-90 radioembolization

Locations (sample)

• Utrecht, Utrecht, Netherlands|52.09083,5.12222

Key Eligibility Criteria

• Patients diagnosed with primary or metastatic liver tumors (any histological type).
• A clinical indication for radioembolization.
• Liver tumors with a diameter ≥ 2 cm.
• Age ≥ 18 years.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →